68 related articles for article (PubMed ID: 8399998)
1. QSAR and molecular modelling of antimuscarinic 7-amino-1-hydroxy-5-heptyn-2-ones.
Mager PP; Mager H; Walther H
Drug Des Discov; 1993 Jun; 10(2):135-56. PubMed ID: 8399998
[TBL] [Abstract][Full Text] [Related]
2. Analogues of oxybutynin. Synthesis and antimuscarinic and bladder activity of some substituted 7-amino-1-hydroxy-5-heptyn-2-ones and related compounds.
Carter JP; Noronha-Blob L; Audia VH; Dupont AC; McPherson DW; Natalie KJ; Rzeszotarski WJ; Spagnuolo CJ; Waid PP; Kaiser C
J Med Chem; 1991 Oct; 34(10):3065-74. PubMed ID: 1920357
[TBL] [Abstract][Full Text] [Related]
3. Quantitative structure-activity relationships in a set of antimuscarinic agents.
Cappello B; Silipo C; Vittoria A; Pratesi P
Farmaco Sci; 1984 Dec; 39(12):991-1007. PubMed ID: 6529988
[TBL] [Abstract][Full Text] [Related]
4. Distance geometry of alpha-substituted 2,2-diphenylpropionate antimuscarinics.
Gordon RK; Breuer E; Padilla FN; Smejkal RM; Chiang PK
Mol Pharmacol; 1989 Nov; 36(5):766-72. PubMed ID: 2586491
[TBL] [Abstract][Full Text] [Related]
5. Bicyclic dioxolanes as potential antimuscarinic agents.
Piergentili A; Angeli P; Giannella M; Pigini M; Quaglia W; Tayebati SK
Arzneimittelforschung; 1996 Feb; 46(2):99-105. PubMed ID: 8720297
[TBL] [Abstract][Full Text] [Related]
6. Quantitative correlations and reexamination of the importance of hydrophobic and steric factors in anticholinergic drug receptor interactions.
Banerjee S; Lien EJ
Pharm Res; 1990 Jul; 7(7):746-50. PubMed ID: 2395804
[TBL] [Abstract][Full Text] [Related]
7. Three-dimensional molecular shape analysis-quantitative structure-activity relationship of a series of cholecystokinin-A receptor antagonists.
Tokarski JS; Hopfinger AJ
J Med Chem; 1994 Oct; 37(21):3639-54. PubMed ID: 7932591
[TBL] [Abstract][Full Text] [Related]
8. Antimuscarinic agents: furan analogs of benzilate esters.
Stubbins JF; Hudgins PM; Murphy DC
J Pharm Sci; 1980 May; 69(5):534-7. PubMed ID: 7381738
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the antimuscarinic and antispasmodic actions of racemic oxybutynin and desethyloxybutynin and their enantiomers with those of racemic terodiline.
Smith ER; Wright SE; Aberg G; Fang Y; McCullough JR
Arzneimittelforschung; 1998 Oct; 48(10):1012-8. PubMed ID: 9825119
[TBL] [Abstract][Full Text] [Related]
10. Selectivity profile of some recent muscarinic antagonists in bovine and guinea-pig trachea and heart.
Roffel AF; Hamstra JJ; Elzinga CR; Zaagsma J
Arch Int Pharmacodyn Ther; 1994; 328(1):82-98. PubMed ID: 7893193
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of new muscarinic receptor antagonists bearing cyclic amidines as cationic heads.
Nicola M; Schiavi GB; Micheletti R; Donetti A; Ladinsky H; Turconi M
Farmaco; 1991 Apr; 46(4):539-53. PubMed ID: 1930552
[TBL] [Abstract][Full Text] [Related]
12. Antispasmodic action of propinox on the isolated human gallbladder: possible mechanism of action.
Baistrocchi RL; Orti E; de los Santos AR; Di Girolamo G; Marti ML; Pico JC
Acta Physiol Pharmacol Ther Latinoam; 1999; 49(3):161-9. PubMed ID: 10797855
[TBL] [Abstract][Full Text] [Related]
13. 1,5-Benzodioxepin derivatives as a novel class of muscarinic M3 receptor antagonists.
Sonda S; Katayama K; Fujio M; Sakashita H; Inaba K; Asano K; Akira T
Bioorg Med Chem Lett; 2007 Feb; 17(4):925-31. PubMed ID: 17188867
[TBL] [Abstract][Full Text] [Related]
14. Antimuscarinic 3-(2-furanyl)quinuclidin-2-ene derivatives: synthesis and structure-activity relationships.
Johansson G; Sundquist S; Nordvall G; Nilsson BM; Brisander M; Nilvebrant L; Hacksell U
J Med Chem; 1997 Nov; 40(23):3804-19. PubMed ID: 9371246
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and activity of novel derivatives of oxybutynin and tolterodine.
Kaur K; Aeron S; Bruhaspathy M; Shetty SJ; Gupta S; Hegde LH; Silamkoti AD; Mehta A; Chugh A; Gupta JB; Sarma PK; Kumar N
Bioorg Med Chem Lett; 2005 Apr; 15(8):2093-6. PubMed ID: 15808475
[TBL] [Abstract][Full Text] [Related]
16. [Structure-activity relationship in the series of muscarinic acetylcholine receptor agonists: three types of agonist-receptor complexes].
Tropsha AE; Nizhniĭ SV; Iaguzhinskiĭ LS
Bioorg Khim; 1985 Oct; 11(10):1391-401. PubMed ID: 4074399
[TBL] [Abstract][Full Text] [Related]
17. General pharmacology of the new antimuscarinic compound vamicamide.
Yamamoto T; Honbo T; Tokoro K; Kojimoto Y; Kodama R; Ohtsuka M; Shimomura K
Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084
[TBL] [Abstract][Full Text] [Related]
18. [Structure-activity relationship in the series of muscarinic acetylcholine receptor antagonists: four types of antagonist-receptor binding].
Tropsha AE; Nizhniĭ SV; Iaguzhinskiĭ LS
Bioorg Khim; 1985 Oct; 11(10):1402-16. PubMed ID: 4074400
[TBL] [Abstract][Full Text] [Related]
19. R and S enantiomers of oxybutynin: pharmacological effects in guinea pig bladder and intestine.
Kachur JF; Peterson JS; Carter JP; Rzeszotarski WJ; Hanson RC; Noronha-Blob L
J Pharmacol Exp Ther; 1988 Dec; 247(3):867-72. PubMed ID: 2849672
[TBL] [Abstract][Full Text] [Related]
20. Quinidine as a muscarinic antagonist: a structural approach.
Ciechanowicz-Rutkowska M; Oleksyn BJ; Suszko-Purzycka A; Lipińska T
J Pharm Sci; 1992 Jun; 81(6):559-64. PubMed ID: 1522494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
